ziprasidone has been researched along with clozapine in 165 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (4.24) | 18.2507 |
| 2000's | 108 (65.45) | 29.6817 |
| 2010's | 43 (26.06) | 24.3611 |
| 2020's | 7 (4.24) | 2.80 |
| Authors | Studies |
|---|---|
| Ewing, FE; Furman, JS; Howard, HR; Jackson, E; Johnson, C; Lowe, JA; Maloney, PR; Morrone, J; Newman, ME; Robinson, GL; Schmidt, AW; Seeger, TF; Seymour, PA; Zorn, SH | 1 |
| De Loore, K; Gommeren, W; Janssen, PF; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van Gompel, P | 1 |
| Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Grinde, E; Herrick-Davis, K; Teitler, M | 1 |
| Bristow, LJ; Hutson, PH; Rowley, M | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Wermuth, CG | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Herrick-Davis, K; Purohit, A; Smith, C; Teitler, M | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Morphy, R; Rankovic, Z | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Farasati, NA; Huang, Y; Randhawa, P | 1 |
| Shahid, M; Walker, GB; Wong, EH; Zorn, SH | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Ablordeppey, SY; Altundas, R; Bricker, B; Jackson, T; Khan, A; Kumar, EV; Roth, BL; Zhu, XY | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Bali, A; Dhir, H; Kumar, A; Malhotra, S; Sharma, A | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Giordanetto, F; Leach, AG; Zachariae, U | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Jensen, AA; Kehler, J; Krogsgaard-Larsen, N | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Chappie, TA; Helal, CJ; Hou, X | 1 |
| Peters, JU | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bojarski, AJ; Bugno, R; Dubiel, K; Hogendorf, A; Hogendorf, AS; Kalinowska-Tłuścik, J; Knutelska, J; Krawczyk, M; Kurczab, R; Lenda, T; Matłoka, M; Moszczyński-Pętkowski, R; Nikiforuk, A; Pieczykolan, J; Pietruś, W; Pilarski, B; Popik, P; Satała, G; Staroń, J; Wieczorek, M; Zajdel, P | 1 |
| Freeman, BB; Rankovic, Z; Yang, L | 1 |
| de Boer, P; de Vries, JB; Kruse, CG; Long, SK; Westerink, BH | 1 |
| Braselton, JP; Reynolds, LS; Rollema, H; Sprouse, JS; Zorn, SH | 1 |
| Allison, DB; Cappelleri, JC; Chandler, LP; Heo, M; Infante, MC; Mentore, JL; Weiden, PJ | 1 |
| Bayle, FJ; Ghaoui, S; Olie, JP | 1 |
| Keck, PE; McElroy, SL; Strakowski, SM | 1 |
| Möller, HJ | 1 |
| McAskill, R; Taylor, DM | 1 |
| Lu, Y; Rollema, H; Schmidt, AW; Sprouse, JS; Zorn, SH | 1 |
| Kapur, S; Remington, G | 1 |
| Hilger, E; Kasper, S | 1 |
| Casey, DE; Zorn, SH | 1 |
| Dekeyne, A; Gobert, A; Millan, MJ; Rivet, JM | 1 |
| Howard, HR; Lebel, LA; Schmidt, AW; Zorn, SH | 1 |
| Sussman, N | 1 |
| Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Weizman, A; Weizman, R | 1 |
| Dai, J; Fowler, WL; Ichikawa, J; Meltzer, HY; O'Laughlin, IA | 1 |
| Nomikos, GG; Rodriguez, DE; Shirazi-Southall, S | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Cussac, D; Duqueyroix, D; Millan, MJ; Newman-Tancredi, A | 1 |
| Jessen, LM | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Kaye, NS | 1 |
| Leander, JD; Wolff, MC | 1 |
| Freeman, MP; Gelenberg, AJ; Gnanadesikan, M | 1 |
| Hedges, D; Jeppson, K; Whitehead, P | 1 |
| Lieberman, JA; Stroup, TS | 1 |
| Kropp, S; Schomerus, G; Ziegenbein, M | 1 |
| Tamminga, CA | 1 |
| Mandrioli, R; Pucci, V; Raggi, MA; Sabbioni, C | 1 |
| Buckley, PF; Glazer, W; Sebastian, CS | 1 |
| Bitter, I | 1 |
| Findling, RL; McNamara, NK | 1 |
| Buchanan, RW; Buckley, PF; Chiles, JA; Conley, RR; Crismon, ML; Ereshefsky, L; Essock, SM; Finnerty, M; Hall, CS; Marder, SR; McEvoy, JP; Miller, A; Miller, DD; Rush, AJ; Saeed, SA; Schooler, NR; Shon, SP; Stroup, S; Tarin-Godoy, B | 1 |
| Dressing, H; Mase, E; Zink, M | 2 |
| Curtis, LH; Dans, PE; Hutchison, S; Krishnan, RR; Masselink, LE; Schulman, KA; Wright, A; Østbye, T | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Citrome, L; Volavka, J | 1 |
| Finkel, S | 1 |
| Katz, IR | 1 |
| Byerly, M; Carmody, T; Holland, R; Li, B; Miller, DR; Montgomery, JH; Varghese, F | 1 |
| Härtter, S; Hiemke, C; Sachse, J | 1 |
| Dubois, D | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Kuehn, BM | 1 |
| Matsui-Sakata, A; Ohtani, H; Sawada, Y | 1 |
| Bruins Slot, LA; Kleven, MS; Newman-Tancredi, A | 1 |
| Berk, M; Bourin, M; Dodd, S; Ivanovski, B; Lagopoulos, J; Malhi, GS; Mitchell, PB | 1 |
| Annable, L; Beauclair, L; Chouinard, G; Kolivakis, TT; Margolese, HC; Miller, R | 1 |
| Bitter, I; Jones, RM; Thompson, C | 1 |
| Kostulski, A; Rabe-Jabłońska, J; Wyszogrodzka-Kucharska, A | 1 |
| Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS | 1 |
| Friedman, AB; Li, X; Rosborough, KM; Roth, KA; Zhu, W | 1 |
| Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
| Calliess, IT; Ziegenbein, M | 1 |
| Campbell, L; Cato, KJ; Clarke, K; Davies, CH; Gordon, L; Gribble, A; Heath, J; Jones, DN; Patel, N; Riley, G; Scott, C; Wood, MD; Worby, A | 1 |
| Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG | 1 |
| Schindehütte, J; Trenkwalder, C | 1 |
| Baumgartner, S; Ebenbichler, C; Edlinger, M; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Rettenbacher, MA | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| De Oliveira, IR; Juruena, MF | 1 |
| Capuano, G; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; McGee, MF; Perkins, DO; Reimherr, F; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Gomberg, R | 1 |
| Goodman, C; Silver, H | 1 |
| Dimpfel, W | 1 |
| Wooten, J | 1 |
| Bartlett, MG; Terry, AV; Zhang, G | 1 |
| Citrome, L | 1 |
| Avorn, J; Brookhart, MA; Choudhry, NK; Mogun, H; Patrick, A; Schneeweiss, S; Setoguchi, S; Wang, PS | 1 |
| Neill, JC; Snigdha, S | 1 |
| Bilder, RM; Galluzzo, A; Gorini, B; Harvey, PD; Loebel, AD; Romeo, F; Sacchetti, E | 1 |
| Carpenter, LL; Philip, NS; Price, LH; Tyrka, AR | 1 |
| Allingham, B; Citrome, L; Jaffe, A; Levine, J; Martello, D | 1 |
| Erickson, CA; McDougle, CJ; Posey, DJ; Stigler, KA | 1 |
| Sikich, L | 1 |
| Dressing, H; Krumm, B; Kuwilsky, A; Zink, M | 1 |
| Croarkin, PE; Emslie, GJ; Mayes, TL | 1 |
| Aliaga, M; Assié, MB; Barbara, M; Bardin, L; Carilla-Durand, E; Malfètes, N; Maraval, M; Newman-Tancredi, A | 1 |
| Galluzzo, A; Gorini, B; Romeo, F; Sacchetti, E; Valsecchi, P; Warrington, L | 2 |
| Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Forstbauer, SI; Freudenreich, O; Goff, DC; Henderson, DC; Miley, K; Sharma, B | 1 |
| Bogers, JP; Starrenburg, FC | 1 |
| Kumar, R; Sachdev, PS | 1 |
| Ayesa, R; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pérez-Iglesias, R; Ramirez-Bonilla, M; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| DeLorenze, G; L'Italien, G; McQuade, R; Newcomer, J; Oliveria, SA; Quesenberry, CP; Tsai, AL; Willey, VJ; Yood, MU | 1 |
| Barbui, C; Boso, M; Cipriani, A | 1 |
| Bhoopathi, PS; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S | 1 |
| Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Srisurapanont, M | 1 |
| Conley, Y; Davies, MA; Roth, BL | 1 |
| Helm, ME; Henderson, C; Martin, BC; Pathak, P; West, D | 1 |
| Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Elsom, SJ; Gurvich, C; Kulkarni, J; McCauley-Elsom, K | 1 |
| Albaugh, VL; Breazeale, S; Elich, TD; Ilkayeva, O; Joyal, JL; Lang, CH; Lynch, CJ; Maresca, KP; Vary, TC; Wenner, BR | 1 |
| Bramness, JG; Gjerden, P; Slørdal, L | 1 |
| Dressing, H; Englisch, S; Krumm, B; Kuwilsky, A; Zink, M | 1 |
| Grignon, S; Roy-Desruisseaux, J | 1 |
| Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; von Wilmsdorff, M | 1 |
| Asenjo Lobos, C; Hunger, H; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Andreotti, S; Gattaz, WF; Lima, FB; Passos-Bueno, MR; Sertié, AL; Sertié, RA; Suzuki, AM | 1 |
| Dudova, I; Hrdlicka, M; Urbanek, T; Zedkova, I | 1 |
| Berkowitz, RL; Docherty, JP; Ni, Q; Parks, JJ; Patel, U | 1 |
| Cho, YM; Jeong, SW; Jung, H; Kim, JH; Kwak, SN; Kwon, OJ; Lee, KW; Oh, JE | 1 |
| Blagojević, D; Lečić-Toševski, D; Miljević, Č; Niketić, V; Nikolić, M; Nikolić-Kokić, A; Spasić, MB | 1 |
| Dietrich-Muszalska, A; Kopka, J; Kwiatkowska, A | 1 |
| Li, CH; Rao, SZ; Shi, L; Zhan, GL; Zhang, H | 1 |
| Abenavoli, E; Bruno, A; Lamberti Castronuovo, E; Micò, U; Muscatello, MR; Pandolfo, G; Scimeca, G; Spina, E; Zoccali, R | 1 |
| Asmal, L; Flegar, SJ; Komossa, K; Leucht, S; Rummel-Kluge, C; Wang, J | 1 |
| Kuntz, KM; Park, T | 1 |
| Buckley, PF | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Fujita, M; Hagino, Y; Hashimoto, M; Ikeda, K; Kasai, S; Kobayashi, K; Meltzer, HY; Setogawa, S; Yamaura, H; Yanagihara, D | 1 |
| Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H | 1 |
| Barbosa, DS; Bonifácio, KL; Brinholi, FF; Casagrande, R; Farias, CC; Higachi, L; Moreira, EG | 1 |
| Blagojević, D; Mijušković, A; Miler, M; Miljević, Č; Milošević, V; Nestorov, J; Nikolić, M; Nikolić-Kokić, A; Oreščanin-Dušić, Z; Spasić, M; Tatalović, N | 1 |
| Ensom, MHH; Johnson, EG; Johnson, HE; Wilby, KJ | 1 |
| Dietrich-Muszalska, A; Kolińska-Łukaszuk, J | 1 |
| Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T | 1 |
| Blagojević, D; Mijović, M; Mijusković, A; Miler, M; Miljević, Č; Milošević, V; Nestorov, J; Nikolić, M; Nikolić-Kokić, A; Oreščanin-Dušić, Z; Spasić, M; Tatalović, N | 1 |
| Jovanović, VB; Mačvanin, MT; Mandić, LM; Nikolić, MR; Nikolić-Kokić, AL; Spasić, SD; Uzelac, TN | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Buchmann, J; Dück, A; Grözinger, M; Häßler, F; Hofmockel, R; Höppner, J; Reinhardt, M; Weirich, S | 1 |
| Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P | 1 |
| Blagojević, D; Brkljačić, J; Miler, M; Miljević, Č; Milošević, V; Nikolić, M; Nikolić-Kokić, A; Oreščanin-Dušić, Z; Platanić Arizanović, L; Spasić, S; Tatalović, N; Vidonja Uzelac, T | 1 |
| Blagojević, D; Brkljačić, J; Mijović, M; Mijušković, A; Miljević, Č; Nestorović, V; Nikolić, M; Nikolić-Kokić, A; Oreščanin-Dušić, Z; Spasić, S; Tatalović, N; Vidonja Uzelac, T | 1 |
| Cvijetić, I; Gligorijević, N; Kokić, AN; Mijatović, A; Miljević, Č; Minić, S; Nikolić, M; Platanić Arizanović, L; Ristivojević, MK | 1 |
| Cañete, T; Fernández-Teruel, A; Lavín, V; Oliveras, I; Río-Álamos, C; Sampedro-Viana, D; Sánchez-González, A; Sanna, F; Tapias-Espinosa, C; Tobeña, A; Torrecilla, P | 1 |
55 review(s) available for ziprasidone and clozapine
| Article | Year |
|---|---|
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Mice; Mice, Transgenic; Nitric Oxide Synthase; Receptor, Serotonin, 5-HT2A; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Receptors, Serotonin; Schizophrenia; Serotonin Antagonists | 2001 |
Selective optimization of side activities: another way for drug discovery.
Topics: Animals; Biological Availability; Combinatorial Chemistry Techniques; Databases, Factual; Drug Design; Humans; Patents as Topic; Pharmaceutical Preparations; Structure-Activity Relationship | 2004 |
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
Polypharmacology - foe or friend?
Topics: Animals; Communicable Diseases; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Polypharmacology; Safety | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Central Nervous System Agents; Drug Delivery Systems; Drug Discovery; Humans; Molecular Structure; Structure-Activity Relationship | 2019 |
Antipsychotic-induced weight gain: a comprehensive research synthesis.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Confidence Intervals; Drug Administration Schedule; Humans; Molindone; Piperazines; Placebos; Psychotic Disorders; Research Design; Thiazoles; Treatment Outcome; Weight Gain | 1999 |
[New antipsychotic agents].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Sulpiride; Thiazoles | 1999 |
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; Depressive Disorder; Dibenzothiazepines; Hostility; Humans; Multicenter Studies as Topic; Olanzapine; Piperazines; Pirenzepine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Suicide; Thiazoles; Treatment Outcome | 2000 |
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Imidazoles; Indoles; Neurotransmitter Agents; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles | 2000 |
Atypical antipsychotics and weight gain--a systematic review.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Risperidone; Sulpiride; Thiazoles; Weight Gain | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Dopamine Antagonists; Drug Monitoring; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Sulpiride; Thiazoles; Treatment Outcome | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Dibenzothiepins; Haloperidol; Humans; Imidazoles; Indoles; Multicenter Studies as Topic; Olanzapine; Piperazines; Pirenzepine; Placebos; Quetiapine Fumarate; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulpiride; Thiazoles | 2000 |
The pharmacology of weight gain with antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Eating; Humans; Olanzapine; Piperazines; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Rats; Receptors, Neurotransmitter; Schizophrenia; Thiazoles; Weight Gain | 2001 |
Review of atypical antipsychotics and weight gain.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Hospitalization; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Research Design; Schizophrenia; Thiazoles; Weight Gain | 2001 |
Use of atypical antipsychotics in mood disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Depressive Disorder, Major; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Risperidone; Thiazoles | 2001 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Clozapine; Cyclohexanecarboxylic Acids; Dibenzothiazepines; Donepezil; Fatty Acids, Omega-3; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Indans; Lamotrigine; Lithium Carbonate; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Risperidone; Thiazoles; Topiramate; Treatment Outcome; Triazines; Valproic Acid | 2003 |
Antipsychotic medication and seizures: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2003 |
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
Topics: Antipsychotic Agents; Benzodiazepines; Chemistry, Pharmaceutical; Clinical Trials as Topic; Clozapine; Cytochrome P-450 Enzyme System; Dibenzothiazepines; Drug Interactions; Drug Monitoring; Humans; Molecular Structure; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2004 |
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Piperazines; Polypharmacy; Quetiapine Fumarate; Quinolones; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
[Current pharmacotherapy of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Serotonin Antagonists; Sulpiride; Thiazoles | 2004 |
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Child; Child Development Disorders, Pervasive; Clozapine; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Tic Disorders | 2004 |
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
Topics: Algorithms; Ambulatory Care; Ambulatory Care Facilities; Antipsychotic Agents; Aripiprazole; Clozapine; Decision Trees; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; Schizophrenic Psychology; Texas; Thiazoles; Treatment Outcome | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Serotonin Antagonists; Thiazoles; Treatment Outcome; United States | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2004 |
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Double-Blind Method; Drug Industry; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Research Support as Topic; Retrospective Studies; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Drug Interactions; Drug Overdose; Dry Eye Syndromes; Humans; Hyperlipidemias; Hypotension; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2005 |
A typical mood stabilizers: a "typical role for atypical antipsychotics.
Topics: Affect; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Secondary Prevention; Sulpiride; Thiazoles | 2005 |
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Incidence; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2005 |
A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Thiazoles; Treatment Outcome | 2006 |
[Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
Topics: Antipsychotic Agents; Body Weight; Clozapine; Dibenzothiazepines; Humans; Hyperlipidemias; Leptin; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles; Weight Gain | 2005 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2006 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder, Major; Dibenzothiazepines; Drug Synergism; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Thiazoles | 2008 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Child; Child Development Disorders, Pervasive; Child, Preschool; Clozapine; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2008 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Thiazoles | 2008 |
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.
Topics: Adiponectin; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus; Humans; Leptin; Obesity; Olanzapine; Piperazines; Quinolones; Receptor, Muscarinic M3; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Histamine; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Weight Gain | 2009 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2009 |
Ziprasidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2009 |
Quetiapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Medication Adherence; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2010 |
Olanzapine versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2010 |
Antipsychotics in pregnancy.
Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes, Gestational; Dibenzothiazepines; Female; Humans; Infant, Newborn; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2010 |
Clozapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2010 |
Risperidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2011 |
Quetiapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Medication Adherence; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2013 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parkinson Disease; Piperazines; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; Urea | 2017 |
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disorders; Olanzapine; Patient Dropouts; Perphenazine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Substance-Related Disorders; Thiazoles | 2018 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
14 trial(s) available for ziprasidone and clozapine
| Article | Year |
|---|---|
Ziprasidone augmentation of clozapine in 11 patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain | 2003 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Over Studies; Dibenzothiazepines; Drug Monitoring; Drug Resistance; Eosinophilia; Female; Follow-Up Studies; Humans; Male; Olanzapine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2006 |
Early changes of plasma lipids during treatment with atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Clozapine; Humans; Lipids; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Triglycerides | 2006 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Follow-Up Studies; Health Status; Humans; National Institute of Mental Health (U.S.); Olanzapine; Patient Dropouts; Perphenazine; Piperazines; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Thiazoles; Treatment Outcome; United States | 2007 |
A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; Drug Resistance; Drug Tolerance; Female; Humans; Italy; Male; Memory Disorders; Neuropsychological Tests; Piperazines; Placebos; Schizophrenia; Schizophrenic Psychology; Thiazoles; Trail Making Test; Treatment Outcome | 2008 |
Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Humans; Long QT Syndrome; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Body Weight; Clozapine; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Italy; Lipids; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Young Adult | 2009 |
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Clozapine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Male; Middle Aged; Morbidity; Olanzapine; Piperazines; Schizophrenia; Thiazoles; Time Factors | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Sulpiride; Thiazoles | 2009 |
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Body Weight; Clozapine; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Italy; Lipids; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Young Adult | 2009 |
Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Humans; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Risperidone; Serotonin Antagonists; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2010 |
A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Triglycerides | 2013 |
Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Italy; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Depressive Disorder, Major; Double-Blind Method; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2015 |
96 other study(ies) available for ziprasidone and clozapine
| Article | Year |
|---|---|
3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Brain; Catalepsy; Clozapine; Dopamine; Drug Design; Humans; Molecular Structure; Phosphatidylinositols; Piperazines; Prazosin; Rats; Receptors, Adrenergic; Receptors, Dopamine; Serotonin Antagonists; Thiazoles | 1996 |
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Topics: Animals; Antipsychotic Agents; Brain; Cells, Cultured; Clozapine; Haloperidol; Humans; Male; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone | 1996 |
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
Topics: Animals; Antipsychotic Agents; COS Cells; Dose-Response Relationship, Drug; Humans; Inositol Phosphates; Radioligand Assay; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Receptor Agonists | 2000 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
Topics: Amino Acid Substitution; Antipsychotic Agents; Cell Line; Cyclic AMP; Humans; Mutagenesis, Site-Directed; Mutation; Radioligand Assay; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.
Topics: Antiviral Agents; BK Virus; Cell Line; Chloroquine; Humans; Microbial Sensitivity Tests; Molecular Structure; Nystatin; Virus Replication | 2007 |
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Topics: Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cloning, Molecular; Clozapine; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Histamine Release; Humans; Inhibitory Concentration 50; Molecular Structure; Olanzapine; Psychotropic Drugs; Radioligand Assay; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Schizophrenia; Substrate Specificity | 2009 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Topics: Animals; Antipsychotic Agents; Apomorphine; Azepines; Butyrophenones; Clozapine; Haloperidol; Lethal Dose 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect.
Topics: Animals; Antipsychotic Agents; Mice; Oxyquinoline; Schizophrenia; Stereotyped Behavior | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Topics: Binding Sites; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Potassium Channel Blockers; Protein Binding; Protein Conformation | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.
Topics: Cell Line; HeLa Cells; Humans; Indoles; Ligands; Protein Binding; Pyrazines; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
Topics: Animals; Cyclic AMP; Cyclic GMP; Humans; Hydrolysis; Mice; Models, Molecular; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats | 2012 |
2-Aminoimidazole-based antagonists of the 5-HT
Topics: Animals; Cells, Cultured; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Design; HEK293 Cells; Hep G2 Cells; Humans; Imidazoles; Male; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Scopolamine; Serotonin Antagonists; Structure-Activity Relationship | 2019 |
Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine; Dopamine Agonists; Extracellular Space; Haloperidol; Male; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Wistar; Reference Values; Risperidone; Tetrahydronaphthalenes; Thiazoles | 1998 |
Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Animals; Benzodiazepines; Clozapine; Desipramine; Dose-Response Relationship, Drug; Male; Neurons; Olanzapine; Piperazines; Pirenzepine; Pyridines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles | 1999 |
5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Clozapine; Corpus Striatum; Dopamine; Haloperidol; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Sensitivity and Specificity; Synaptic Transmission; Thiazoles; Time Factors | 2000 |
Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
Topics: Animals; Antipsychotic Agents; Benzopyrans; Clozapine; Discrimination Learning; Dopamine; Dopamine Agonists; Haloperidol; Humans; Male; Oxazines; Piperazines; Pyrrolidines; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Receptor Agonists; Tetrahydronaphthalenes; Thiazoles | 2001 |
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding Sites; Binding, Competitive; Cell Line; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Haloperidol; Humans; Neurons; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Risperidone; Serotonin; Serotonin Antagonists; Thiazoles | 2001 |
Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Dose-Response Relationship, Drug; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Humans; Membranes; Piperazines; Piperidines; Pyridines; Pyrimidinones; Pyrrolidines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Thiazoles; Thioridazine; Tritium | 2001 |
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Cholinesterase Inhibitors; Clozapine; Corpus Striatum; Haloperidol; Male; Nucleus Accumbens; Olanzapine; Oxotremorine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Scopolamine; Sulpiride; Thiazoles; Thioridazine | 2002 |
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Dialysis Solutions; Dopamine Antagonists; Extracellular Space; Haloperidol; Hippocampus; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Wistar; Risperidone; Serotonin Antagonists; Thiazoles; Thioridazine | 2002 |
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Topics: Animals; Antipsychotic Agents; CHO Cells; Clozapine; Cricetinae; Enzyme Activation; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunoblotting; Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Pyrrolidines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles | 2002 |
The value of atypical antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Drug Labeling; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Risperidone; Safety; Schizophrenia; Thiazoles; United States | 2002 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Comparison of the effects of antipsychotics on a delayed radial maze task in the rat.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Dose-Response Relationship, Drug; Food Deprivation; Haloperidol; Male; Maze Learning; Memory; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles | 2003 |
Schizophrenia, VI: Treatments.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Perphenazine; Piperazines; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2003 |
Ziprasidone-induced Pisa syndrome after clozapine treatment.
Topics: Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Piperazines; Schizophrenia; Serotonin Antagonists; Thiazoles | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
[Ziprasidone-augmentation of clozapine].
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Schizophrenia, Paranoid; Thiazoles | 2004 |
Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Databases, Factual; Diabetes Mellitus; Dibenzothiazepines; Drug Prescriptions; Female; Humans; Incidence; Insurance Claim Reporting; Male; Middle Aged; Multivariate Analysis; Olanzapine; Outpatients; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; Thioridazine; Time Factors; United States | 2005 |
Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection.
Topics: Adult; Automation; Benzodiazepines; Chromatography, High Pressure Liquid; Clozapine; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Reproducibility of Results; Schizophrenia; Sensitivity and Specificity; Spectrophotometry; Thiazoles; Time Factors | 2005 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
FDA warns antipsychotic drugs may be risky for elderly.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Drug Approval; Drug Labeling; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risperidone; Schizophrenia; Thiazoles | 2005 |
Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dioxanes; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Excitatory Amino Acid Antagonists; Haloperidol; Interpersonal Relations; Male; Phencyclidine; Piperazines; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Remoxipride; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles; Tropanes | 2005 |
Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Male; Mice; Mice, Inbred C57BL; Olanzapine; Phosphorylation; Piperazines; Quetiapine Fumarate; Risperidone; Selective Serotonin Reuptake Inhibitors; Serine; Thiazoles; Time Factors | 2007 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration | 2006 |
Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Schizophrenia, Paranoid; Thiazoles | 2006 |
Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Biogenic Monoamines; CHO Cells; Clozapine; Cricetinae; Dibenzothiazepines; Dopamine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Synaptic Transmission; Thiazoles | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles | 2006 |
Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Laughter; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Psychoses, Substance-Induced; Quetiapine Fumarate; Thiazoles | 2007 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
Possible case of allopurinol causing relapse of psychosis.
Topics: Adult; Allopurinol; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Therapy, Combination; Female; Gout; Gout Suppressants; Hallucinations; Humans; Piperazines; Psychoses, Substance-Induced; Recurrence; Schizophrenia, Paranoid; Thiazoles | 2007 |
Impairment in error monitoring predicts poor executive function in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Memory, Short-Term; Neuropsychological Tests; Olanzapine; Piperazines; Reaction Time; Risperidone; Schizophrenia; Self Efficacy; Severity of Illness Index; Thiazoles | 2007 |
Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Corpus Striatum; Dibenzothiazepines; Dose-Response Relationship, Drug; Electroencephalography; Female; Hippocampus; Injections, Intraperitoneal; Male; Motor Activity; Movement; Olanzapine; Piperazines; Prefrontal Cortex; Quetiapine Fumarate; Rats; Rats, Inbred F344; Reticular Formation; Risperidone; Thiazoles; Time Factors | 2007 |
Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chromatography, Liquid; Clozapine; Haloperidol; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Rats; Reproducibility of Results; Risperidone; Tandem Mass Spectrometry; Thiazoles | 2007 |
Show me the evidence: using number needed to treat.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Confidence Intervals; Data Interpretation, Statistical; Decision Making; Evidence-Based Medicine; Humans; Likelihood Functions; Olanzapine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Databases, Factual; Dementia; Dibenzothiazepines; Drug Utilization Review; Health Services for the Aged; Humans; Olanzapine; Pharmaceutical Services; Piperazines; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Stroke; Thiazoles; Treatment Outcome | 2007 |
Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Female; Haloperidol; Matched-Pair Analysis; Phencyclidine; Piperazines; Rats; Rats, Inbred Strains; Schizophrenia; Schizophrenic Psychology; Social Behavior; Social Behavior Disorders; Thiazoles | 2008 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Humans; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2008 |
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benzofurans; Benzoxazoles; Benzylamines; Blood Glucose; Clozapine; Corticosterone; Cyclopentanes; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Thiazoles | 2008 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Diabetes Mellitus; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Piperazines; Quinolones; Retrospective Studies; Thiazoles; United States | 2009 |
Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Resistance; HEK293 Cells; Humans; Mutagenesis, Site-Directed; Neuroleptic Malignant Syndrome; Nursing Research; Olanzapine; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Quinolones; Receptor, Serotonin, 5-HT2A; Risperidone; Thiazoles | 2011 |
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Drug Utilization; Evidence-Based Medicine; Female; Humans; Infant; Insurance Claim Review; Male; Medicaid; Mental Disorders; Off-Label Use; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2010 |
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carnitine; Clozapine; Energy Metabolism; Fatty Acids, Nonesterified; Female; Haloperidol; Insulin Resistance; Lipolysis; Male; Malonyl Coenzyme A; Mice; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles; Vitamin B Complex | 2012 |
Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Chlorprothixene; Cholinergic Antagonists; Clopenthixol; Clozapine; Drug Prescriptions; Female; Follow-Up Studies; Haloperidol; Humans; Logistic Models; Male; Methotrimeprazine; Middle Aged; Mortality; Norway; Odds Ratio; Piperazines; Registries; Thiazoles | 2010 |
Protracted, dose-dependent weight loss after addition of ziprasidone to a stable regimen of clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Piperazines; Schizophrenia; Thiazoles; Time Factors; Weight Loss | 2010 |
The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Clozapine; Eating; Exploratory Behavior; Haloperidol; Hypothalamus; Leptin; Male; Motor Activity; Piperazines; Rats; Rats, Wistar; Receptors, Leptin; Thiazoles; Time Factors; Weight Gain | 2010 |
Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Haloperidol; Humans; Olanzapine; Piperazines; Thiazoles; Weight Gain | 2011 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome | 2011 |
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothiazepines; Humans; Missouri; Olanzapine; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics.
Topics: Adipocytes, Brown; Adipogenesis; Adipokines; Animals; Antipsychotic Agents; Cell Differentiation; Cell Line; Cell Survival; Clozapine; Dibenzothiazepines; Gene Expression Regulation; Humans; Mice; Piperazines; Quetiapine Fumarate; Schizophrenia; Thiazoles; Weight Gain | 2012 |
Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study).
Topics: Adult; Amisulpride; Antioxidants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Catalase; Clozapine; Dibenzothiazepines; Enzyme Activation; Erythrocytes; Glutathione Peroxidase; Glutathione Reductase; Humans; Imidazoles; Indoles; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Sulpiride; Superoxide Dismutase; Superoxide Dismutase-1; Thiazoles; Treatment Outcome; Young Adult | 2013 |
The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; In Vitro Techniques; Lipid Peroxidation; Male; Piperazines; Thiazoles; Thiobarbituric Acid Reactive Substances | 2013 |
Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Male; Markov Chains; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2014 |
Update on putative novel antipsychotics.
Topics: Antipsychotic Agents; Brain Injuries; Clozapine; Cognition Disorders; Drug Therapy, Combination; Employment, Supported; Humans; Piperazines; Schizophrenia; Thiazoles | 2014 |
Involvement of cholinergic system in hyperactivity in dopamine-deficient mice.
Topics: Acetylcholine; Akathisia, Drug-Induced; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Central Nervous System Stimulants; Choline O-Acetyltransferase; Clozapine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Extracellular Space; Haloperidol; Levodopa; Locomotion; Mice, Inbred C57BL; Piperazines; Psychomotor Agitation; Thiazoles | 2015 |
Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models.
Topics: Antioxidants; Antipsychotic Agents; Benzodiazepines; Biphenyl Compounds; Clozapine; Free Radical Scavengers; Haloperidol; Humans; Models, Biological; Neutrophil Activation; Neutrophils; Olanzapine; Picrates; Piperazines; Quetiapine Fumarate; Reactive Oxygen Species; Risperidone; Tetradecanoylphorbol Acetate; Thiazoles | 2016 |
Effects of antipsychotic drug administration on antioxidative defense enzymes in male rat kidney.
Topics: Animals; Antioxidants; Antipsychotic Agents; Clozapine; Imidazoles; Indoles; Kidney; Male; Oxidative Stress; Piperazines; Random Allocation; Rats; Rats, Wistar; Thiazoles | 2016 |
Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood; Clozapine; Female; Humans; Lipid Peroxidation; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Thiazoles; Thiobarbituric Acid Reactive Substances; Young Adult | 2018 |
Clozapine, ziprasidone, and sertindole-induced morphological changes in the rat heart and their relationship to antioxidant enzymes function.
Topics: Animals; Antioxidants; Antipsychotic Agents; Clozapine; Heart; Imidazoles; Indoles; Male; Myocardium; Oxidation-Reduction; Piperazines; Rats; Rats, Wistar; Thiazoles | 2018 |
Opposite clozapine and ziprasidone effects on the reactivity of plasma albumin SH-group are the consequence of their different binding properties dependent on protein fatty acids content.
Topics: Animals; Clozapine; Fatty Acids; Humans; Male; Piperazines; Protein Binding; Rats; Rats, Wistar; Serum Albumin; Spectrometry, Fluorescence; Spectrophotometry; Sulfhydryl Compounds; Thiazoles | 2019 |
[Electroconvulsive Therapy - A beneficial and well tolerated therapy in children and adolescents with schizophrenia].
Topics: Adolescent; Catatonia; Child; Clozapine; Combined Modality Therapy; Electroconvulsive Therapy; Humans; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2020 |
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Humans; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Substance Abuse Detection; Suicide; Sulpiride; Tandem Mass Spectrometry; Thiazoles | 2020 |
Effects of several atypical antipsychotics closapine, sertindole or ziprasidone on hepatic antioxidant enzymes: Possible role in drug-induced liver dysfunction.
Topics: Animals; Antioxidants; Antipsychotic Agents; Clozapine; Imidazoles; Indoles; Liver; Liver Diseases; Male; Piperazines; Rats; Rats, Wistar; Thiazoles | 2021 |
Antipsychotic Drug-Mediated Adverse Effects on Rat Testicles May Be Caused by Altered Redox and Hormonal Homeostasis.
Topics: Animals; Antioxidants; Antipsychotic Agents; Clozapine; Homeostasis; Male; Oxidation-Reduction; Prolactin; Rats; Testis; Testosterone | 2022 |
Human Hemoglobin and Antipsychotics Clozapine, Ziprasidone and Sertindole: Friends or Foes?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Molecular Docking Simulation; Olanzapine | 2023 |
Atypical antipsychotics attenuate MK801-induced social withdrawal and hyperlocomotion in the RHA rat model of schizophrenia-relevant features.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dizocilpine Maleate; Male; Rats; Schizophrenia; Social Isolation | 2023 |